Ashwagandha and Liver Safety: What the Case Reports and Clinical Data Show

Ashwagandha is everywhere. It is in stress gummies at Target, in adaptogen blends at Whole Foods, in pre-workout formulas, in sleep supplements, and in standalone capsules sold by hundreds of brands online. Global demand has grown by an estimated 15 to 20 percent annually over the past five years, driven by clinical trials showing real effects on cortisol, anxiety, and sleep quality.

Against that backdrop of explosive growth, a parallel literature has been accumulating, in hepatology journals rather than wellness blogs, documenting cases of clinically apparent liver injury in people taking commercial ashwagandha products. Not many cases. But enough of them, with enough consistency in their clinical presentation, that the pattern can no longer be dismissed as coincidence.

The central tension in ashwagandha liver safety is that the controlled trial data and the post-market case report data tell different stories. Understanding why they diverge (and what that means for you) is the point of this article.

The Trial Record: Clean

In randomized controlled trials, ashwagandha has not been implicated in causing serum enzyme elevations during therapy. No serious hepatic adverse events have been reported across studies enrolling participants at doses of 300 to 600 mg of root extract daily for 8 to 12 weeks.

The NIH LiverTox database, the most authoritative reference for supplement-induced liver injury in the United States: states this explicitly in its ashwagandha monograph, last updated December 3, 2024 (NIH LiverTox, 2024).

A 2024 safety study published in the Journal of Ayurveda and Integrative Medicine specifically evaluated clinical safety and tolerability of a standardized ashwagandha root extract in healthy volunteers and found no abnormalities in liver function markers (Philips et al., 2024).

So at the clinical trial level, controlled conditions, standardized extracts, verified suppliers, monitored participants, ashwagandha looks safe for the liver. This is real data, and it matters.

The problem is what happens outside those controlled conditions.

The Case Report Record: Not Clean

The LiverTox monograph itself acknowledges the other side: ashwagandha "recently has been implicated in cases of clinically apparent liver injury." As of the December 2024 update, the database notes that 23 cases of clinically apparent liver injury due to ashwagandha have been reported, with typical onset of cholestatic hepatitis after a month of use.

The case literature has been growing fast enough to generate multiple independent review efforts:

Growth of Published Case Reports Over Time

The India Case Series (Philips et al., 2023)

The currently largest published case series comes from multiple medical centers in India. Philips et al. retrospectively analyzed 23 patients with ashwagandha-related liver injury from January 2019 to December 2022 and reported in detail on 8 patients who consumed single-ingredient formulations: excluding anyone taking multi-herb products where attribution would be ambiguous (Philips et al., 2023).

Key findings from this series:

• Cholestatic hepatitis was the most common presentation
• The cohort was male-predominant
• Five of 23 patients had underlying chronic liver disease
• Three patients developed acute-on-chronic liver failure, all three died
• Chemical analysis of the implicated products did not detect other hepatotoxic substances, strengthening the causal attribution to ashwagandha itself

That last point deserves emphasis. A common counterargument to herbal hepatotoxicity claims is that the product might have been contaminated or adulterated. In this series, toxicology testing was performed and came back clean. The liver injury was attributed to ashwagandha's own bioactive compounds, specifically withanolides, which the authors proposed may cause irreversible adduction to hepatocellular DNA.

The 2026 Scoping Review (McIntyre et al.)

A 2026 scoping review published in Cureus systematically mapped the clinical characteristics of ashwagandha-associated liver injury across the published literature through December 2025. The review identified a reproducible clinical syndrome and confirmed that "probable" or "likely" causality assessments recurred across geographically distinct reports: India, the United States, Europe, and elsewhere (McIntyre et al., 2026).

The review also queried the FDA Adverse Event Reporting System (FAERS) using the terms "ashwagandha" and "Withania somnifera" and found additional signals consistent with the published case reports.

The 2026 Egyptian Systematic Review

A separate systematic review published in The Egyptian Journal of Internal Medicine compiled all available case reports and case series, providing a comprehensive chronological mapping of ashwagandha DILI globally. The authors noted that the number of reports has accelerated in proportion to the supplement's rising popularity and called for stricter regulatory oversight of herbal supplement safety (EJIM, 2026).

The 2025 Spanish Case

Casiano-Manzano et al. (2025) published a case from Spain in Revista Española de Enfermedades Digestivas documenting ashwagandha-induced hepatotoxicity with the editorial title "Changing perspectives: unveiling the risks", reflecting the shift in clinical opinion from "generally safe herb" to "herb with reproducible hepatotoxicity potential" (PMID: 37982556).

The 2024 Case (Almuzghi et al.)

A 22-year-old healthy female developed moderate to severe liver injury after taking ashwagandha capsules at the manufacturer's recommended dose. Symptoms appeared within 30 hours, unusually rapid, suggesting possible hypersensitivity rather than cumulative toxicity. The case resolved after discontinuation (Almuzghi et al., 2024).

The 2025 DILI Review Context

A 2025 review titled "Common Causes of Drug-Induced Liver Injury", published in PMC, explicitly listed ashwagandha alongside green tea extract, turmeric, and kratom as herbal supplements with emerging DILI signals. The review noted that while most patients recover after discontinuation, acute liver failure, death, and the need for emergency liver transplantation have been reported (PMC, 2025).

The Clinical Pattern

Across the published cases, the liver injury presents with striking consistency. Onset usually falls between 2 and 12 weeks after starting ashwagandha, though outliers exist, with the Almuzghi case presenting within 30 hours. The injury is most often cholestatic (centered on the bile ducts) or mixed, with some hepatocellular (liver-cell-centered) cases; the 2026 HCA Healthcare systematic literature review found 49% hepatocellular, 24% mixed, and 19% cholestatic across a broader dataset.

Jaundice, the yellowing of skin and eyes, is the hallmark symptom, but patients also report itching without rash, dark urine, pale stools, fatigue, nausea, malaise, and right upper abdominal discomfort. Severity ranges widely, from asymptomatic enzyme elevations found incidentally on blood work to acute liver failure requiring emergency transplantation, and the Indian series documented three deaths. Most cases resolve within weeks to months after stopping the supplement, although jaundice can linger for weeks after enzymes begin improving. Where RUCAM causality scores were calculated, they typically landed at "probable" or "highly probable", the two highest tiers on the standardized drug-induced liver injury scale.

Why Do Trials and Case Reports Disagree?

This is the question that matters most, and there are several plausible answers that are not mutually exclusive:

Start with the math of rare events. If ashwagandha causes liver injury at a rate of 1 in 10,000 users (a number I am using illustratively, the actual incidence is unknown), a clinical trial enrolling 100 participants has a 99% probability of not seeing a single case. You would need to enroll tens of thousands to reliably detect an event that rare. No ashwagandha trial has come close to that size.

Idiosyncratic drug reactions are, by definition, too rare for clinical trials to detect. Acetaminophen's liver toxicity is dose-dependent and predictable. Ashwagandha's appears to be idiosyncratic, unpredictable, unrelated to dose in most cases, and likely dependent on individual genetic or metabolic factors that have not been characterized.

Product variability is a second factor. Clinical trials use standardized, quality-controlled extracts from specific suppliers. The commercial market sells everything from KSM-66 (a branded, clinically studied extract) to uncharacterized bulk powder from undisclosed sources. Withanolide concentrations vary. Extraction methods vary. Contamination profiles vary.

Whether the liver injury is caused by ashwagandha's own withanolides or by contaminants, adulterants, or specific extraction byproducts in lower-quality products remains an open question. The Indian case series found no contaminants, pointing toward the herb itself. But other cases may involve product quality issues.

Duration and dose accumulation may also play a part. Most trials run 8 to 12 weeks. Some case reports involve longer-term use. It is possible that cumulative withanolide exposure over months creates a hepatotoxic burden that shorter trials do not capture: though the 30-hour onset in the Almuzghi case argues against accumulation as the universal mechanism.

Finally, underreporting distorts the picture. The real number of cases is almost certainly higher than the published count. Many consumers do not connect their symptoms to a supplement. Many physicians do not ask about supplement use. Many cases resolve on their own when the consumer stops the supplement for unrelated reasons and never attributes the improvement to discontinuation.

Who Is at Higher Risk?

The case literature identifies several risk factors that appear disproportionately:

The case literature points to several factors that recur disproportionately. Pre-existing liver disease is the most serious: the Indian series found that all three deaths occurred in patients with underlying chronic liver disease, since cirrhosis or fatty liver reduces the reserve capacity to handle an idiosyncratic insult. Concurrent hepatotoxic medications or supplements, such as high-dose acetaminophen, statins, alcohol, or green tea extract, add to the burden, and regular or heavy alcohol use compounds it further because alcohol is independently hepatotoxic. Taking multiple supplements at once makes the cause harder to identify if injury occurs and may create additive hepatic stress. Individual genetic factors likely matter too, since drug-metabolizing enzyme polymorphisms (CYP2E1, CYP3A4, UGT variants) may predispose certain people, though this has not been studied for ashwagandha specifically.

What to Monitor

The pragmatic approach for people who choose to take ashwagandha despite the case report literature:

Baseline liver function testing (ALT, AST, total bilirubin, alkaline phosphatase, GGT) before starting ashwagandha. This gives you a reference point. If your baseline is abnormal, resolve that before adding a supplement with any hepatotoxicity signal.

Repeat testing at 4 to 8 weeks. This covers the typical onset window for ashwagandha-associated liver injury. If enzymes are stable and within normal limits, the acute risk window has likely passed, though continued vigilance is reasonable.

Immediate discontinuation and medical evaluation if you develop any of the following:

• Yellowing of skin or eyes
• Persistent itching without visible rash
• Dark urine (tea-colored or cola-colored)
• Pale or clay-colored stools
• Unexplained fatigue lasting more than a few days
• Right upper abdominal discomfort or fullness
• New-onset nausea without obvious cause

These symptoms should prompt liver function testing, not a "wait and see" approach. Catching drug-induced liver injury early, when enzymes are elevated but before frank jaundice develops, dramatically improves outcomes.

Recommended Monitoring Protocol

The cost of this monitoring protocol, a baseline and one follow-up liver panel, is approximately $50-100 without insurance, $0-30 with insurance. That is a trivial investment against the risk of undetected liver injury progressing to jaundice or worse.

Product Quality Matters, But Is Not the Whole Story

The instinct to blame product quality, contamination, adulteration, unverified suppliers, is understandable and partly justified. The supplement market is poorly regulated, and low-quality products are real. Using a standardized, clinically studied extract like KSM-66 or Sensoril from a reputable brand with third-party testing reduces several categories of risk.

But product quality is not the whole story. The Philips et al. case series tested the implicated products and found no contaminants. The proposed mechanism (withanolide-mediated adduction to hepatocellular DNA) implicates ashwagandha's own bioactive compounds, not something that accidentally got into the bottle.

This means even a high-quality, properly standardized ashwagandha product carries some non-zero risk of idiosyncratic liver injury in susceptible individuals. That risk is low. But it is not zero. And pretending otherwise, as most ashwagandha marketing does, is not consistent with the published evidence.

The Dose-Duration Matrix: When Risk Increases

Not all ashwagandha use carries the same risk profile. The published hepatotoxicity cases cluster around specific patterns, and understanding them helps distinguish low-risk from higher-risk usage.

Most cases involved: doses above 600 mg/day of concentrated extract, continuous use for 2+ months without breaks, multi-ingredient products combining ashwagandha with other potentially hepatotoxic botanicals, or pre-existing liver conditions / concurrent hepatotoxic medication use.

By contrast, clean trial safety data typically involves standardized root extract at 300–600 mg/day for 8–12 weeks in screened, healthy participants not taking other hepatotoxic substances. The gap between trial conditions and real-world use explains much of the discrepancy.

A practical risk-stratification framework:

• Lower risk: 300–600 mg/day of standardized root extract (KSM-66 or Sensoril), 8–12 week cycles, healthy adults, no hepatotoxic medications, baseline liver panel on file
• Moderate risk: 600+ mg/day, continuous use beyond 12 weeks, multi-ingredient formulations, concurrent moderate CYP-metabolized drugs
• Higher risk: Any dose with pre-existing liver disease, autoimmune hepatitis history, known hepatotoxic drugs (high-dose acetaminophen, certain antifungals, isoniazid), or heavy alcohol use

Extract Types and Safety Profiles

KSM-66: Full-spectrum root extract standardized to ≥5% withanolides. Most widely studied: the majority of positive RCT data comes from this extract. Water-based extraction without chemical solvents. Trial doses: 300–600 mg/day.

Sensoril: Root and leaf extract standardized to ≥10% withanolides. Leaf inclusion means higher withanolide concentration at lower doses (125–250 mg/day in trials). Different phytochemical profile from root-only extracts.

Generic/unstandardized: Products listing "ashwagandha root powder" without withanolide standardization are impossible to dose-compare with the clinical literature. They may contain variable withanolide levels and lack batch-to-batch consistency.

For liver safety: most case reports did not specify extract type. We cannot say whether hepatotoxicity risk differs between extract types. What we know is that KSM-66 and Sensoril have the most clinical trial safety data.

The Autoimmune Hypothesis

Several case reports describe liver injury with autoimmune hepatitis features, elevated immunoglobulins, positive autoantibodies, and biopsy findings consistent with immune-mediated inflammation rather than direct toxic injury.

Ashwagandha is marketed as an "immune modulator." The same immunostimulatory properties that attract consumers, enhanced NK cell activity, increased IgM/IgG, improved lymphocyte proliferation, may, in genetically predisposed individuals, trigger autoaggression against liver tissue.

Autoimmune hepatitis has known genetic susceptibility linked to HLA-DR3 and HLA-DR4 alleles. Individuals carrying these alleles may be at higher risk from botanical immunostimulants: not just ashwagandha, but also echinacea and astragalus.

This hypothesis is untested prospectively. But if correct, the practical implication is that people with personal or family history of autoimmune conditions, particularly autoimmune hepatitis, Hashimoto's, or lupus, should exercise extra caution with ashwagandha and other immunostimulatory supplements.

Drug Interactions Affecting Liver Risk

Ashwagandha is metabolized through CYP3A4 and CYP2D6 (for a full breakdown, see our ashwagandha drug interactions guide). Drugs sharing these pathways can compete, potentially increasing blood levels of either substance.

• Thyroid medications (levothyroxine): Ashwagandha can increase thyroid hormone production, creating additive effects. Thyroid storms (rare) can cause secondary liver injury.
• Immunosuppressants: Ashwagandha's immune-stimulating properties may counteract these drugs, and immune system involvement plays a role in idiosyncratic drug-induced liver injury.
• Benzodiazepines: Both are GABAergic. Additive sedation is the primary concern, but both are also hepatically metabolized, CYP competition could alter clearance.
• Diabetes medications: Ashwagandha lowers blood sugar. Combining with metformin or sulfonylureas increases hypoglycemia risk.

None of these interactions have been formally studied in combination trials. When in doubt, discuss ashwagandha use with your prescriber.

Frequently Asked Questions

Can ashwagandha cause liver damage?

In clinical trials at standard doses (300–600 mg/day for 8–12 weeks), ashwagandha has not caused liver damage. Rare case reports of liver injury exist, mostly with higher doses, longer use, multi-ingredient products, or autoimmune predisposition. The mechanism appears idiosyncratic and immune-mediated, affecting a small genetically susceptible subset rather than being dose-dependent across the population.

In clinical trials at standard doses (300–600 mg/day for 8–12 weeks), ashwagandha has not caused liver damage. However, rare case reports of liver injury exist: primarily in the context of higher doses, longer continuous use, multi-ingredient products, or individuals with pre-existing liver conditions or autoimmune predisposition. The mechanism appears to be idiosyncratic (immune-mediated) rather than direct toxicity, meaning it affects a small subset of genetically predisposed individuals rather than being dose-dependent in the general population.

Should I get liver tests before taking ashwagandha?

A baseline liver panel is reasonable, especially if you take CYP3A4 or CYP2D6 drugs, have a personal or family history of autoimmune conditions, or plan doses above 600 mg/day. For healthy adults on a standardized extract at 300–600 mg/day with no risk factors, it is prudent but not mandatory. If you test, repeat at 8–12 weeks.

A baseline liver panel (ALT, AST, ALP, bilirubin) before starting ashwagandha is reasonable, especially if you take any medications metabolized by CYP3A4 or CYP2D6, have a personal or family history of autoimmune conditions, or plan to take doses above 600 mg/day. For healthy adults taking a standardized extract at 300–600 mg/day with no other risk factors, baseline testing is prudent but not strictly mandatory. If you do get baseline labs, repeat them at 8–12 weeks to catch any early signal.

How do I know if ashwagandha is affecting my liver?

The earliest sign is elevated liver enzymes (ALT, AST) on a blood test, often before symptoms. Symptomatic injury can show as fatigue, nausea, appetite loss, dark urine, jaundice, or right upper abdominal pain. If any occur, stop ashwagandha immediately and see your physician for a liver panel. Prompt discontinuation has led to full recovery in published cases.

The earliest sign would be elevated liver enzymes (ALT and AST) on a blood test, often before symptoms appear. Symptomatic liver injury can present as fatigue, nausea, loss of appetite, dark urine, jaundice (yellowing of skin or eyes), or right upper abdominal discomfort. If any of these occur while taking ashwagandha, stop supplementation immediately and see your physician for a liver panel. Early detection and discontinuation have led to full recovery in all published case reports where the reaction was caught promptly.

Is KSM-66 safer than other ashwagandha extracts?

KSM-66 has the most clinical trial safety data of any ashwagandha extract, but we cannot definitively call it safer because most liver-injury case reports did not identify the extract used. What KSM-66 offers is better-characterized batch consistency and more evidence of clean liver panels at labeled doses. Other extracts are not proven unsafe, just less studied.

KSM-66 has the most clinical trial safety data of any ashwagandha extract. But we cannot definitively say it is "safer" because most case reports of liver injury did not identify which extract was used. What KSM-66 offers is better-characterized batch consistency and a larger body of evidence showing clean liver panels at labeled doses. This does not mean other extracts are unsafe, it means they have less published safety data.

Can I take ashwagandha with alcohol?

No formal study has examined this combination. Both ashwagandha and alcohol are processed by hepatic CYP enzymes, and heavy drinking independently damages the liver. Occasional moderate drinking with standard-dose ashwagandha is unlikely to compound risk meaningfully. For heavy drinkers, the alcohol is the real concern, and addressing intake matters more than the supplement stack.

No formal study has examined this combination. Both ashwagandha and alcohol are processed by hepatic CYP enzymes, and heavy alcohol use independently damages the liver. For occasional moderate drinking, concurrent ashwagandha use at standard doses is unlikely to compound liver risk meaningfully. For heavy drinkers, the alcohol itself is the liver concern, and adding any supplement (ashwagandha included) should be discussed with a physician. If you drink heavily, addressing alcohol intake is a higher priority than optimizing your supplement stack.

Who should avoid ashwagandha?

Ashwagandha is safe for most people in trials, but rare idiosyncratic liver injury means several groups should avoid it or proceed only with monitoring. The liver risk appears immune-mediated and unpredictable rather than dose-dependent. People with autoimmune or liver conditions, those on interacting medications, and pregnant women should avoid ashwagandha or use it only under medical supervision.

People with autoimmune or liver conditions. Ashwagandha's immunostimulatory activity may trigger autoimmune-like hepatitis in susceptible individuals. Those with a personal or family history of autoimmune disease, or with existing liver disease, should be especially cautious.

Anyone on CYP-metabolized or immune-related drugs. Ashwagandha is metabolized through CYP3A4 and CYP2D6 and can interact with thyroid medication, immunosuppressants, sedatives, and diabetes drugs. Discuss it with your prescriber first.

Pregnant or breastfeeding women. Animal studies show abortifacient effects at high doses, and no human pregnancy safety data exists. Ashwagandha should be avoided during pregnancy and breastfeeding.

High-dose or long-term users. Most case reports involve doses above 600 mg/day, prolonged use, or multi-ingredient products. Staying within studied doses (300–600 mg/day for 8–12 weeks) and getting baseline liver testing lowers risk.

The Bottom Line

Ashwagandha is well-tolerated in the large majority of users. The controlled trial data supports this, and the absolute risk of clinically significant liver injury is almost certainly low.

But a reproducible pattern of idiosyncratic liver injury has been documented across multiple countries, product types, patient populations, and independent case series. Three deaths have been attributed to ashwagandha in the published literature. The 2025 DILI review now lists ashwagandha alongside green tea extract and turmeric as an herbal supplement with an emerging hepatotoxicity signal.

The clinical trials say ashwagandha is generally safe. The case reports say it is not safe for everyone. Both statements are supported by evidence, and responsible supplementation means acknowledging both rather than pretending the case reports do not exist.

Baseline liver function testing, an 8-week recheck, and awareness of early warning symptoms cost almost nothing and eliminate the scenario where liver injury progresses silently to a dangerous stage.

---

Written by Tao Wu. This article is based on peer-reviewed case reports, systematic reviews, and the NIH LiverTox database. YourHealthier sells ashwagandha supplements. See our editorial policy for how we research and write.

Last updated: September 19, 2026

If you take medications metabolized by the liver, have a personal or family history of autoimmune or liver conditions, or notice any symptoms of liver stress, stop and see your physician rather than working from this article alone. The content here is educational and is not medical advice. Ashwagandha is a dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease.

---

References

NIH LiverTox. Ashwagandha. National Institute of Diabetes and Digestive and Kidney Diseases. Last updated December 3, 2024. NIH

Philips CA, Theruvath AH, Ravindran R, Rajesh S, Augustine P. Ashwagandha-induced liver injury, A case series from India and literature review. *Hepatology Communications*. 2023;7(10):e0270. PubMed: 37756041

McIntyre D, Nguyen P, Kim Y, Meyer B, Salloum M. Ashwagandha (Withania somnifera)-Associated Liver Injury: A Scoping Review of Clinical Characteristics and Safety Considerations. *Cureus*. 2026;18(5):e109764. PubMed: 42367407

Ashwagandha-induced liver injury: a systematic review of case reports. *The Egyptian Journal of Internal Medicine*. 2026. Springer

Almuzghi F, Abdelmalik A, Abuhlaiga M. Ashwagandha-Induced Hepatic Injury: A Case Report. *Cureus*. 2024;16(10):e71576. PMC: 11564894

Casiano-Manzano S, Torres-Larrubia M, Masa-Caballero A, et al. Changing perspectives: unveiling the risks of ashwagandha-induced hepatotoxicity. *Rev Esp Enferm Dig*. 2025;117(5):288-289. PubMed: 37982556

Common Causes of Drug-Induced Liver Injury in 2025. *PMC*. 2025. PMC: 13554482

Philips CA, Theruvath AH. A comprehensive review on the hepatotoxicity of herbs used in the Indian (Ayush) systems of alternative medicine. *Medicine*. 2024;103:e37903. PubMed: 38640296

Philips CA, Theruvath AH. A comprehensive review on the hepatotoxicity of herbs used in the Indian (Ayush) systems of alternative medicine. *Medicine (Baltimore)*. 2024;103(16):e37903.

Teplitsky D, Sebaugh J, et al. Ashwagandha-Associated Liver Injury: A Systematic Literature Review. HCA Healthcare North Texas GME Research, 2026. HCA Scholarly Commons